FDA Approved Products

1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
Active:Lifecycle: PeakClear all
LOTEMAX SM
loteprednol etabonate
Peak
Bausch + Lomb
OPHTHALMIC · GEL
post-operative inflammationpain following ocular surgery
2019
NDA
0/100
LUMAKRAS
sotorasib
Peak
Amgen
ORAL · TABLET
metastatic non-small cell lung cancer (NSCLC)determined by an FDA-approved test+4
2021
NDA
0/100
LUMASON
sulfur hexafluoride
Peak
Bracco
INTRAVENOUS · FOR SUSPENSION
2014
NDA
0/100
LUPKYNIS
voclosporin
Peak
Aurinia Pharmaceuticals
ORAL · CAPSULE
2021
NDA
0/100
LUTATHERA
lutetium lu 177 dotatate
Peak
INTRAVENOUS · SOLUTION
older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)including foregut+2
2018
NDA
0/100
LUZU
luliconazole
Peak
Bausch + Lomb
TOPICAL · CREAM
2013
SMNDA
0/100
LYBALVI
olanzapine and samidorphan l-malate
Peak
Alkermes
ORAL · TABLET
Schizophrenia
2021
NDA
0/100
LYNPARZA
olaparib
Peak
AstraZeneca
ORAL · CAPSULE
2014
NDA
0/100
LYNPARZA
olaparib
Peak
AstraZeneca
ORAL · TABLET
2017
NDA
0/100
LYTGOBI
futibatinib
Peak
Taiho Oncology
ORAL · TABLET
2022
SMNDA
0/100
LYVISPAH
baclofen
Peak
PharmaIN
ORAL · GRANULES
2021
NDA
0/100
MAVENCLAD
cladribine
Peak
ORAL · TABLET
relapsing forms of multiple sclerosis (MS)to include relapsing-remitting disease+2
2019
NDA
0/100
MAVYRET
glecaprevir and pibrentasvir
Peak
AbbVie
ORAL · TABLET
2017
SMNDA
0/100
MAVYRET
glecaprevir and pibrentasvir
Peak
AbbVie
ORAL · PELLETS
2021
SMNDA
0/100
MAYZENT
siponimod
Peak
Novartis
ORAL · TABLET
2019
NDA
0/100
MEKINIST
trametinib
Peak
Novartis
ORAL · TABLET
Usage (1lung cancer+1
2013
SMNDA
0/100
MEKINIST
trametinib
Peak
Novartis
ORAL · SOLUTION
Usage (1lung cancer+1
2023
SMNDA
0/100
MEKTOVI
binimetinib
Peak
Pfizer
ORAL · TABLET
lung cancer
2018
SMNDA
0/100
METAXALONE
metaxalone
Peak
ORAL · TABLET
2015
NDA
0/100
MIDAZOLAM IN 0.9% SODIUM CHLORIDE
midazolam
Peak
INTRAVENOUS · SOLUTION
2021
NDA
0/100
MINOCIN
minocycline hydrochloride
Peak
INJECTION · INJECTABLE
infections caused by the following Gram-negative bacteriainfections caused by the following Gram-positive bacteria+6
1972
NDA
0/100
MINOLIRA
minocycline hydrochloride
Peak
ORAL · TABLET, EXTENDED RELEASE
2017
NDA
0/100
MIRVASO
brimonidine tartrate
Peak
Galderma
TOPICAL · GEL
2013
NDA
0/100
MITIGARE
colchicine
Peak
Hikma
ORAL · CAPSULE
gout flares in adultsgout flares in adults ()
2014
NDA
0/100
← PreviousPage 39 of 55Next →